From Financial Modeling Prep: 2025-06-04 20:00:00

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotech company specializing in antifungal treatments for challenging infections. With a ROIC of -60.19%, SCYX struggles to cover its WACC of 9.98%, resulting in a -6.03 ROIC to WACC ratio. Peers like Cidara Therapeutics and Bellerophon Therapeutics face similar challenges in generating returns on invested capital.

Cidara Therapeutics (CDTX) also grapples with a negative ROIC of -72.84% against a WACC of 7.71%, leading to a -9.45 ROIC to WACC ratio. This indicates difficulties in generating sufficient returns relative to capital costs. Bellerophon Therapeutics (BLPH) faces even greater challenges with a ROIC of -728.98% and a WACC of 33.39%, resulting in a -21.84 ROIC to WACC ratio, highlighting significant inefficiencies in capital utilization.



Read more at Financial Modeling Prep:: Understanding SCYNEXIS’s Financial Efficiency in t…